首页|Telaprevir/boceprevir era: From bench to bed and back

Telaprevir/boceprevir era: From bench to bed and back

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
Hepatitis C virus (HCV) infects approximately 200 million people worldwide.Interferon-based therapies have dominated over the past two decades.However,the overall response rates remain suboptimal.Thanks to the tremendous effort from both academia and industry,two serine protease inhibitors telaprevir and boceprevir for treating chronic hepatitis C have finally reached the clinic.Although these compounds are only approved for combination use with interferon and ribavirin in genotype 1 HCV infected chronic patients,the management of HCV patients however is now evolving incredibly.Here,we overviewed a series of landmark studies,regarding the clinical development of telaprevir and boceprevir.We discussed the mechanism-of-action of telaprevir/boceprevir and their potential application in HCV-positive liver transplantation patients.We further emphasized some emerging concerns with perspective of further development in this field.

TelaprevirBoceprevirMechanism-of-actionClinical efficacyLiver transplantation patientInterferonRibavirin

Qiuwei Pan、Maikel P Peppelenbosch、Harry LA Janssen、Robert J de Knegt

展开 >

Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, 3015 CE Rotterdam, The Netherlands

Foundation for Liver and Gastrointestinal Research (SLO)Netherlands Organisation for Scientific Research (NOW)

VENI-grant 916-13-032

2012

10.3748/wjg.v18.i43.6183

世界胃肠病学杂志(英文版)
太原消化病研治中心

世界胃肠病学杂志(英文版)

SCI
影响因子：1.001
ISSN：1007-9327
年,卷(期)：2012.18(43)
  • 1
  • 45